Wednesday, May 27, 2015 1:54:47 PM
http://campaign.r20.constantcontact.com/render?ca=1ba7aebc-e835-4753-9a50-090cc0de0a10&c=a605dc10-4eb0-11e4-b0b7-d4ae5292bb50&ch=a609fac0-4eb0-11e4-b0b7-d4ae5292bb50
May 27, 2015 NASDAQ:NWBO
Dear Jim,
Wanted to call your attention to the attached release from this morning providing the details of NW Bio's upcoming presentation this weekend in Chicago, on the survival data to date and other findings of the DCVax-Direct Phase I/II Trial for all types of inoperable solid tumors.
Hope you can tune in to the live webcast and hear about this new DCVax-Direct information.
Sincerely,
Leslie J. Goldman
Senior Vice President for Business Development
Embargoed for Release On Wednesday, May 27, 2015, at 8:30 a.m.
NW BIO TO PRESENT OVERVIEW OF DCVAX-DIRECT PHASE I TRIAL
IN CHICAGO THIS WEEKEND
Will Include Survival Data To Date and Other Findings
BETHESDA, MD, May 27, 2015 - Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Dr. Marnix L. Bosch, Chief Technical Officer of the Company, will be making an Industry Expert Theater Presentation at the 2015 ASCO Annual Meeting in Chicago on Saturday, May 30, 2015, from 3 to 4 p.m. CDT, at the Industry Expert Theater in McCormick Place.
Dr. Bosch will provide an overview of the Company's DCVax-Direct Phase I trial, including new information about survival data collected to date and other findings. Dr. Bosch will also discuss these other findings in connection with the Company's plans for DCVax-Direct Phase II trials.
Dr. Bosch's presentation will be webcast live at nwbio.com/webcast
Not an official presentation of the 2015 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation. Not CME-accredited.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM